Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Verapamil treatment of β-cells

ABSTRACT: Verapamil treatment of β-cells

PROVIDER: PRJNA962576 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24326910_1.fastq.gz	Fastqsanger.gz
	SRR24326910_2.fastq.gz	Fastqsanger.gz
	SRR24326911_1.fastq.gz	Fastqsanger.gz
	SRR24326911_2.fastq.gz	Fastqsanger.gz
	SRR24326912_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Verapamil treatment of β-cells

Project description:In this study, we investigated the molecular and cellular mechanisms of verapamil treatment on β-cell function and survival using MIN6 cells. Verapamil's molecular processes were studied using transcriptomic data. MTT, cell count, and flow cytometry assessed cell proliferation, growth, and cycle. MIN6 cell function was assessed by glucose-stimulated insulin release and total insulin content. Seahorse and metabolic stress kits examined metabolic activity and oxygen consumption rate. The protective impact of verapamil on MIN6 cells was evaluated by challenging the verapamil treated cell with streptozotocin, T1D-cytomix, or T2D-cytomix cocktail. Our results demonstrate that verapamil treatment induced higher proliferation of MIN6 cells, altered expression of various proteins and genes, improved insulin secretion in hyperglycemic conditions, increased basal and maximal respiration levels, along with β-cell survival against streptozotocin, T1D-, or T2D-cytomix-induced toxicity, and rendered a protective effect.

2023-08-30 | GSE230803 | GEO

Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes

Project description:Currently, no oral medications are available for individuals suffering from type 1 diabetes (T1D). Our randomized placebo-controlled phase 2 trial recently revealed that oral verapamil has short- term beneficial effects in subjects with new-onset type 1 diabetes (T1D) 1. However, what exact biological changes verapamil elicits in humans with T1D, how long they may last, and how to best monitor any associated therapeutic success has remained elusive. We therefore now conducted extended analyses of the effects of continuous verapamil use over a 2-year period, performed unbiased proteomics analysis of serum samples and assessed changes in proinflammatory T-cell markers in subjects receiving verapamil or just standard insulin therapy. In addition, we determined the verapamil-induced changes in human islets using RNA sequencing. Our present results reveal that verapamil regulates the thioredoxin system and promotes an anti-oxidative and anti-apoptotic gene expression profile in human islets, reverses T1D-induced elevations in circulating proinflammatory T-follicular-helper cells and interleukin-21 and normalizes serum levels of chromogranin A (CHGA), a recently identified T1D autoantigen 2,3. In fact, proteomics identified CHGA as the top serum protein altered by verapamil and as a potential therapeutic marker. Moreover, continuous use of oral verapamil delayed T1D progression, promoted endogenous beta cell function and lowered insulin requirements and serum CHGA levels for at least 2 years and these benefits were lost upon discontinuation. Thus, the current studies provide crucial mechanistic and clinical insight into the beneficial effects of verapamil in T1D.

2021-12-03 | GSE181328 | GEO

Transcriptional Response of Mycobacterium tuberculosis H37Rv to Verapamil

Project description:To understand the response of M. tuberculosis (MTB) to the drug verapamil, we performed transcriptomics on MTB bacilli exposed to the drug.

2018-08-02 | GSE118021 | GEO

International Verapamil SR/Trandolapril [INVEST] Genes Study

Project description:International Verapamil SR/Trandolapril [INVEST] Genes Study

| PRJNA686451 | ENA

International Verapamil SR/Trandolapril [INVEST] Genes Study

Project description:International Verapamil SR/Trandolapril [INVEST] Genes Study

| PRJNA686452 | ENA

Gene expression in melanoma cells following treatment with IFN-beta

Project description:Gene expression in melanoma cells following treatment with IFN-beta

| PRJNA513347 | ENA

Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases

Project description:This study will be conducted in subjects with refractory colorectal carcinoma with unresectable liver metastases. The purposes of the study are: * to evaluate the safety and any harmful effects of an intravenous injection of Ad.hIFN-β; * help determine whether the virus carrying the interferon-beta gene will enter the bloodstream and liver tumor cells and cause the cancer cells to die.

| 2012584 | ecrin-mdr-crc

Transcriptional Response of Mycobacterium tuberculosis H37Rv to Verapamil

Project description:Transcriptional Response of Mycobacterium tuberculosis H37Rv to Verapamil

| PRJNA484020 | ENA

HUH VP30 cells with and without interferon α and β treatment

Project description:HUH VP30 cells with and without interferon α and β treatment

| PRJNA417084 | ENA

Gene expression in melanoma cells following treatment with IFN-beta

Project description:To further determine the candidate genes which expressed in four melanoma cells and melanocyte after treatment with IFN-β, total RNA was extracted from melanoma cells, which have different sensitivities to IFN-β, and melanocyte after treatment with or without IFN-β at a concentration of 1,000 IU/ml for 48 h. For expression profiling, oligonucleotide microarray analysis was performed at Hokkaido System Science (Sapporo, Japan) using an Agilent Human Genomic microarray 8 × 60 K version 2.0 (Agilent Technologies, Santa Clara, CA). Then, we focused on two candidate genes, CXCL-10 and IL-24, which are associated with the sensistibity of melanoma cells to IFN-β. We examined whether CXCL10 and IL-24 directly or indirectly cause sensitivitiy of melanoma to IFN-β.

2019-01-08 | GSE124759 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data